Charles River Laboratories Other Current Assets 2010-2025 | CRL
Charles River Laboratories other current assets from 2010 to 2025. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Charles River Laboratories other current assets for the quarter ending March 31, 2025 were $0.100B, a 1.19% increase year-over-year.
- Charles River Laboratories other current assets for 2024 were $0.106B, a 26.89% increase from 2023.
- Charles River Laboratories other current assets for 2023 were $0.083B, a 22.5% decline from 2022.
- Charles River Laboratories other current assets for 2022 were $0.108B, a 10.55% increase from 2021.
| Charles River Laboratories Annual Other Current Assets (Millions of US $) |
|
|---|---|
| 2024 | $106 |
| 2023 | $83 |
| 2022 | $108 |
| 2021 | $97 |
| 2020 | $73 |
| 2019 | $56 |
| 2018 | $49 |
| 2017 | $81 |
| 2016 | $45 |
| 2015 | $47 |
| 2014 | $45 |
| 2013 | $87 |
| 2012 | $84 |
| 2011 | $79 |
| 2010 | $77 |
| 2009 | $112 |
| Charles River Laboratories Quarterly Other Current Assets (Millions of US $) |
|
|---|---|
| 2025-03-31 | $100 |
| 2024-12-31 | $106 |
| 2024-09-30 | $102 |
| 2024-06-30 | $111 |
| 2024-03-31 | $99 |
| 2023-12-31 | $83 |
| 2023-09-30 | $93 |
| 2023-06-30 | $113 |
| 2023-03-31 | $92 |
| 2022-12-31 | $108 |
| 2022-09-30 | $97 |
| 2022-06-30 | $107 |
| 2022-03-31 | $82 |
| 2021-12-31 | $97 |
| 2021-09-30 | $247 |
| 2021-06-30 | $122 |
| 2021-03-31 | $72 |
| 2020-12-31 | $73 |
| 2020-09-30 | $74 |
| 2020-06-30 | $65 |
| 2020-03-31 | $62 |
| 2019-12-31 | $56 |
| 2019-09-30 | $77 |
| 2019-06-30 | $69 |
| 2019-03-31 | $56 |
| 2018-12-31 | $49 |
| 2018-09-30 | $43 |
| 2018-06-30 | $50 |
| 2018-03-31 | $53 |
| 2017-12-31 | $81 |
| 2017-09-30 | $86 |
| 2017-06-30 | $68 |
| 2017-03-31 | $44 |
| 2016-12-31 | $45 |
| 2016-09-30 | $53 |
| 2016-06-30 | $67 |
| 2016-03-31 | $62 |
| 2015-12-31 | $47 |
| 2015-09-30 | $84 |
| 2015-06-30 | $74 |
| 2015-03-31 | $111 |
| 2014-12-31 | $45 |
| 2014-09-30 | $107 |
| 2014-06-30 | $108 |
| 2014-03-31 | $88 |
| 2013-12-31 | $87 |
| 2013-09-30 | $105 |
| 2013-06-30 | $93 |
| 2013-03-31 | $93 |
| 2012-12-31 | $84 |
| 2012-09-30 | $65 |
| 2012-06-30 | $75 |
| 2012-03-31 | $81 |
| 2011-12-31 | $79 |
| 2011-09-30 | $78 |
| 2011-06-30 | $89 |
| 2011-03-31 | $89 |
| 2010-12-31 | $77 |
| 2010-09-30 | $72 |
| 2010-06-30 | $74 |
| 2010-03-31 | $74 |
| 2009-12-31 | $112 |
| 2009-09-30 | $61 |
| 2009-06-30 | $109 |
| 2009-03-31 | $103 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.445B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $144.179B | 27.04 |
| CVS Health (CVS) | United States | $86.198B | 10.71 |
| Elevance Health (ELV) | United States | $84.314B | 10.88 |
| Cencora (COR) | United States | $57.484B | 20.00 |
| DiDi Global (DIDIY) | China | $23.485B | 24.95 |
| Natera (NTRA) | United States | $22.963B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.509B | 17.45 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.205B | 0.00 |
| Solventum (SOLV) | United States | $12.912B | 13.67 |
| CochLear (CHEOY) | Australia | $12.870B | 0.00 |
| ICON (ICLR) | Ireland | $11.851B | 11.02 |
| Revvity (RVTY) | United States | $11.644B | 20.04 |
| Viatris (VTRS) | United States | $10.704B | 3.68 |
| Avantor (AVTR) | United States | $9.363B | 13.60 |
| HealthEquity (HQY) | United States | $9.068B | 39.72 |
| Medpace Holdings (MEDP) | United States | $8.818B | 23.42 |
| Sonic Healthcare (SKHHY) | Australia | $8.465B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.269B | 25.15 |
| BrightSpring Health Services (BTSG) | United States | $4.058B | 37.23 |
| Sotera Health (SHC) | United States | $3.225B | 18.32 |
| Surgery Partners (SGRY) | United States | $2.781B | 36.17 |
| Alignment Healthcare (ALHC) | United States | $2.722B | 0.00 |
| Concentras Parent (CON) | United States | $2.652B | 15.33 |
| Organon (OGN) | United States | $2.594B | 2.76 |
| GeneDx Holdings (WGS) | United States | $2.556B | 98.45 |
| PACS (PACS) | United States | $1.958B | 0.00 |
| Ardent Health (ARDT) | United States | $1.904B | 8.12 |
| Progyny (PGNY) | United States | $1.840B | 40.49 |
| Premier (PINC) | United States | $1.796B | 13.63 |
| GoodRx Holdings (GDRX) | United States | $1.761B | 35.21 |
| Teladoc Health (TDOC) | United States | $1.412B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.181B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.171B | 8.91 |
| CareDx (CDNA) | United States | $1.074B | 16.77 |
| Agilon Health (AGL) | United States | $0.956B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.919B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.840B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.806B | 7.54 |
| Nutex Health (NUTX) | United States | $0.658B | 9.96 |
| LifeMD (LFMD) | United States | $0.615B | 0.00 |
| Embecta (EMBC) | United States | $0.542B | 3.65 |
| InnovAge Holding (INNV) | United States | $0.532B | 0.00 |
| Enhabit (EHAB) | United States | $0.482B | 39.62 |
| Auna S.A (AUNA) | Luxembourg | $0.470B | 10.58 |
| SBC Medicals (SBC) | United States | $0.464B | 0.00 |
| Omada Health (OMDA) | $0.460B | 0.00 | |
| Sonida Senior Living (SNDA) | United States | $0.459B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.312B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.249B | 0.00 |
| Beauty Health (SKIN) | United States | $0.244B | 0.00 |
| So-Young (SY) | China | $0.209B | 0.00 |
| Oncology Institute (TOI) | United States | $0.200B | 0.00 |
| DocGo (DCGO) | United States | $0.172B | 28.17 |
| Pheton Holdings (PTHL) | China | $0.115B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.096B | 0.00 |
| KindlyMD (NAKA) | United States | $0.089B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.075B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.056B | 0.00 |
| ModivCare (MODV) | United States | $0.051B | 0.00 |
| Biodesix (BDSX) | United States | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.036B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.033B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |